Genentech/OSI Tarceva NDA Filing Will Wait For Phase III Monotherapy Data

OSI hopes to be in a position to file a Tarceva NDA in early 2004, when data in refractory non-small cell lung cancer patients is expected

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet